A Review of Immunotherapeutic Approaches for Substance Use Disorders: Current Status and Future Prospects
Muhammet Celik,1 Brian Fuehrlein2,3 1Research Division, VA Connecticut Healthcare System, West Haven, CT, USA; 2Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA; 3Mental Health Service Line, VA Connecticut Healthcare System, West Haven, CT, USACorrespondence: Brian Fuehrlein, Me...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2022-09-01
|
| Series: | ImmunoTargets and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/a-review-of-immunotherapeutic-approaches-for-substance-use-disorders-c-peer-reviewed-fulltext-article-ITT |
| _version_ | 1818029018801242112 |
|---|---|
| author | Celik M Fuehrlein B |
| author_facet | Celik M Fuehrlein B |
| author_sort | Celik M |
| collection | DOAJ |
| description | Muhammet Celik,1 Brian Fuehrlein2,3 1Research Division, VA Connecticut Healthcare System, West Haven, CT, USA; 2Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA; 3Mental Health Service Line, VA Connecticut Healthcare System, West Haven, CT, USACorrespondence: Brian Fuehrlein, Mental Health Service Line, VA Connecticut Healthcare System, 950 Campbell Ave, West Haven, CT, 06516, Tel +1-203-932-5711 x4471, Fax +1-203-937-4904, Email brian.fuehrlein@yale.eduAbstract: Substance use disorders (SUDs) have been a major public health challenge for decades and continue to cause significant morbidity and mortality worldwide. Due to limitations in pharmacologic treatment options, there remains a significant need for the development of novel immunotherapeutic approaches. In this review, we discuss the therapeutic potential of vaccines for SUDs. Although early preclinical animal studies were optimistic and successful, few vaccines have reached human clinical trials. Only nicotine and cocaine vaccines have successfully advanced to Phase 3 clinical trials and neither are currently available as a treatment option. Various innovative approaches in vaccine design have been made to overcome limitations and improve immunogenicity, including the use of nanoparticles, synthetic haptens, and more immunogenic adjuvants. While success has thus far been elusive, with substantial scientific advancements in vaccine technology, immunotherapy remains a promising and viable option for the treatment of SUDs.Keywords: substance use disorder, vaccines, nicotine, opioid, cocaine, methamphetamine |
| first_indexed | 2024-12-10T05:13:01Z |
| format | Article |
| id | doaj.art-ed9647de29124d18816cdf68fd53e535 |
| institution | Directory Open Access Journal |
| issn | 2253-1556 |
| language | English |
| last_indexed | 2024-12-10T05:13:01Z |
| publishDate | 2022-09-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | ImmunoTargets and Therapy |
| spelling | doaj.art-ed9647de29124d18816cdf68fd53e5352022-12-22T02:01:03ZengDove Medical PressImmunoTargets and Therapy2253-15562022-09-01Volume 11556678627A Review of Immunotherapeutic Approaches for Substance Use Disorders: Current Status and Future ProspectsCelik MFuehrlein BMuhammet Celik,1 Brian Fuehrlein2,3 1Research Division, VA Connecticut Healthcare System, West Haven, CT, USA; 2Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA; 3Mental Health Service Line, VA Connecticut Healthcare System, West Haven, CT, USACorrespondence: Brian Fuehrlein, Mental Health Service Line, VA Connecticut Healthcare System, 950 Campbell Ave, West Haven, CT, 06516, Tel +1-203-932-5711 x4471, Fax +1-203-937-4904, Email brian.fuehrlein@yale.eduAbstract: Substance use disorders (SUDs) have been a major public health challenge for decades and continue to cause significant morbidity and mortality worldwide. Due to limitations in pharmacologic treatment options, there remains a significant need for the development of novel immunotherapeutic approaches. In this review, we discuss the therapeutic potential of vaccines for SUDs. Although early preclinical animal studies were optimistic and successful, few vaccines have reached human clinical trials. Only nicotine and cocaine vaccines have successfully advanced to Phase 3 clinical trials and neither are currently available as a treatment option. Various innovative approaches in vaccine design have been made to overcome limitations and improve immunogenicity, including the use of nanoparticles, synthetic haptens, and more immunogenic adjuvants. While success has thus far been elusive, with substantial scientific advancements in vaccine technology, immunotherapy remains a promising and viable option for the treatment of SUDs.Keywords: substance use disorder, vaccines, nicotine, opioid, cocaine, methamphetaminehttps://www.dovepress.com/a-review-of-immunotherapeutic-approaches-for-substance-use-disorders-c-peer-reviewed-fulltext-article-ITTsubstance use disordervaccinesnicotineopioidcocainemethamphetamine |
| spellingShingle | Celik M Fuehrlein B A Review of Immunotherapeutic Approaches for Substance Use Disorders: Current Status and Future Prospects ImmunoTargets and Therapy substance use disorder vaccines nicotine opioid cocaine methamphetamine |
| title | A Review of Immunotherapeutic Approaches for Substance Use Disorders: Current Status and Future Prospects |
| title_full | A Review of Immunotherapeutic Approaches for Substance Use Disorders: Current Status and Future Prospects |
| title_fullStr | A Review of Immunotherapeutic Approaches for Substance Use Disorders: Current Status and Future Prospects |
| title_full_unstemmed | A Review of Immunotherapeutic Approaches for Substance Use Disorders: Current Status and Future Prospects |
| title_short | A Review of Immunotherapeutic Approaches for Substance Use Disorders: Current Status and Future Prospects |
| title_sort | review of immunotherapeutic approaches for substance use disorders current status and future prospects |
| topic | substance use disorder vaccines nicotine opioid cocaine methamphetamine |
| url | https://www.dovepress.com/a-review-of-immunotherapeutic-approaches-for-substance-use-disorders-c-peer-reviewed-fulltext-article-ITT |
| work_keys_str_mv | AT celikm areviewofimmunotherapeuticapproachesforsubstanceusedisorderscurrentstatusandfutureprospects AT fuehrleinb areviewofimmunotherapeuticapproachesforsubstanceusedisorderscurrentstatusandfutureprospects AT celikm reviewofimmunotherapeuticapproachesforsubstanceusedisorderscurrentstatusandfutureprospects AT fuehrleinb reviewofimmunotherapeuticapproachesforsubstanceusedisorderscurrentstatusandfutureprospects |